1. Very doubtful the prostaglandin theory fails. 2 different companies were both willing to take on the cost to trial a drug for hair loss (which is very risky, since most have failed), after 2 years of preclinical research. Both claimed they were very impressed with the science. More than likely, they have the data to back this up.
2. Saying that SM will start their phase 3, if phase 2 was successful, in July 2016, when phase 2 is up in October literally makes no sense. There was a very quick turnaround between phase 1 and the massive 300 participant phase 2, of only 3 months. If successful, they could take the recruits they already had for phase 2 (300) and continue.
3. Bim, perhaps needed another drug like Seti to complement it, and for them to want to move forward.
4. The 21st century cures act becomes law within 10 days of being signed, and the modernization of clinical trials is generally applicable. Yes, cancer drugs etc will take precedent and get approval maybe after phase 2, but this bill is an overhaul to change the way clinical trials are carried out. They are applying the law to the process of discovery, development, and delivery, and not just for certain drugs. Otherwise, the law would be favoring certain companies and certain drugs only.
5. That "2019" quote is here: http://www.reuters.com/article/2013/...9400UW20130501
It refers to Darpin, not Bimatoprost. Whoever's been spreading that, misread the quote, and ran with it.
2. Saying that SM will start their phase 3, if phase 2 was successful, in July 2016, when phase 2 is up in October literally makes no sense. There was a very quick turnaround between phase 1 and the massive 300 participant phase 2, of only 3 months. If successful, they could take the recruits they already had for phase 2 (300) and continue.
3. Bim, perhaps needed another drug like Seti to complement it, and for them to want to move forward.
4. The 21st century cures act becomes law within 10 days of being signed, and the modernization of clinical trials is generally applicable. Yes, cancer drugs etc will take precedent and get approval maybe after phase 2, but this bill is an overhaul to change the way clinical trials are carried out. They are applying the law to the process of discovery, development, and delivery, and not just for certain drugs. Otherwise, the law would be favoring certain companies and certain drugs only.
5. That "2019" quote is here: http://www.reuters.com/article/2013/...9400UW20130501
It refers to Darpin, not Bimatoprost. Whoever's been spreading that, misread the quote, and ran with it.
Comment